Funds raised will support ongoing Phase II(b) clinical trial in Basal Cell Carcinoma Nevus Syndrome, an orphan cancer hereditary disease requiring life-long therapy with no approved pharmaceutical treatment License and Manufacturing Partner Mayne Pharma invests $2.8MM PR Newswire TAMPA, Fla. and SAN DIEGO, June 1, 2016 TAMPA, Fla. and SAN DIEGO, June 1, 2016 /PRNewswire/ — HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announcedRead more
- Research on Lodonal for HIV related GI complications featured in Plus Magazine
- Cannabis Strategic Ventures and Sunniva Inc. Enter Into Cannabis Extraction Services Agreement
- Precision Therapeutics Merger with Helomics Corp. Accelerates Personalized Cancer Treatment Strategies
- Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System
- PHI Group Partners with Fintech Green Investment Company
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More